{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:00:16Z","timestamp":1778886016669,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,19]]},"DOI":"10.7759\/cureus.97231","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:31:47Z","timestamp":1763559107000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Effectiveness of Oral Relugolix in Advanced Prostate Cancer: A Structured Review of Current Primary Research"],"prefix":"10.7759","author":[{"given":"Adnan","family":"Higgi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carys","family":"Melvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abdelrasheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla P","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019, 10:63-89. 10.14740\/wjon1191","journal-title":"World J Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01614-6","article-title":"Prostate cancer, pathophysiology and recent developments in management: a narrative review","volume":"26","author":"Almeeri MN","year":"2024","unstructured":"Almeeri MN, Awies M, Constantinou C. Prostate cancer, pathophysiology and recent developments in management: a narrative review. Curr Oncol Rep. 2024, 26:1511-9. 10.1007\/s11912-024-01614-6","journal-title":"Curr Oncol Rep"},{"key":"ref3","unstructured":"National Institute for Health and Care Excellence (NICE). Prostate cancer. diagnosis and management. (2021). Accessed: October 16, 2025: https:\/\/www.nice.org.uk\/guidance\/ng131."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60111727","article-title":"The effect of androgen deprivation therapy on the cardiovascular system in advanced prostate cancer","volume":"60","author":"Reiss AB","year":"2024","unstructured":"Reiss AB, Vasalani S, Albert J, et al.. The effect of androgen deprivation therapy on the cardiovascular system in advanced prostate cancer. Medicina (Kaunas). 2024, 60:1727. 10.3390\/medicina60111727","journal-title":"Medicina (Kaunas)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of Degarelix versus Leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes RD","year":"2021","unstructured":"Lopes RD, Higano CS, Slovin SF, et al.. Cardiovascular safety of Degarelix versus Leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021, 144:1295-307. 10.1161\/CIRCULATIONAHA.121.056810","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore ND","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, et al.. Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020, 382:2187-96. 10.1056\/NEJMoa2004325","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194854","article-title":"Relugolix vs. Leuprolide effects on castration resistance-free survival from the phase 3 HERO study in men with advanced prostate cancer","volume":"15","author":"Saad F","year":"2023","unstructured":"Saad F, George DJ, Cookson MS, et al.. Relugolix vs. Leuprolide effects on castration resistance-free survival from the phase 3 HERO study in men with advanced prostate cancer. Cancers (Basel). 2023, 15:4854. 10.3390\/cancers15194854","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.03.009","article-title":"Impact of concomitant prostate cancer medications on efficacy and safety of Relugolix versus Leuprolide in men with advanced prostate cancer","volume":"21","author":"George DJ","year":"2023","unstructured":"George DJ, Saad F, Cookson MS, et al.. Impact of concomitant prostate cancer medications on efficacy and safety of Relugolix versus Leuprolide in men with advanced prostate cancer. Clin Genitourin Cancer. 2023, 21:383-392.e2. 10.1016\/j.clgc.2023.03.009","journal-title":"Clin Genitourin Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.7279","article-title":"Efficacy and safety of radiotherapy plus Relugolix in men with localized or advanced prostate cancer","volume":"10","author":"Spratt DE","year":"2024","unstructured":"Spratt DE, George DJ, Shore ND, et al.. Efficacy and safety of radiotherapy plus Relugolix in men with localized or advanced prostate cancer. JAMA Oncol. 2024, 10:594-602. 10.1001\/jamaoncol.2023.7279","journal-title":"JAMA Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2743","article-title":"Population PK and semimechanistic PK\/PD modeling and simulation of Relugolix effects on testosterone suppression in men with prostate cancer","volume":"113","author":"Lee TY","year":"2023","unstructured":"Lee TY, Pierrillas PB, Lin YW, de Greef R, Zandvliet AS, Schindler E, Migoya E. Population PK and semimechanistic PK\/PD modeling and simulation of Relugolix effects on testosterone suppression in men with prostate cancer. Clin Pharmacol Ther. 2023, 113:124-34. 10.1002\/cpt.2743","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.001","article-title":"The oral gonadotropin-releasing hormone receptor antagonist Relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial","volume":"78","author":"Dearnaley DP","year":"2020","unstructured":"Dearnaley DP, Saltzstein DR, Sylvester JE, et al.. The oral gonadotropin-releasing hormone receptor antagonist Relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial. Eur Urol. 2020, 78:184-92. 10.1016\/j.eururo.2020.03.001","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1289249","article-title":"Early biochemical outcomes following neoadjuvant\/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer","volume":"13","author":"Gallagher L","year":"2023","unstructured":"Gallagher L, Xiao J, Hsueh J, et al.. Early biochemical outcomes following neoadjuvant\/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. Front Oncol. 2023, 13:1289249. 10.3389\/fonc.2023.1289249","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02634-7","article-title":"Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix vs leuprolide: subgroup analysis from HERO study in advanced prostate cancer","volume":"40","author":"Shore ND","year":"2023","unstructured":"Shore ND, Mehlhaff BA, Cookson MS, et al.. Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix vs leuprolide: subgroup analysis from HERO study in advanced prostate cancer. Adv Ther. 2023, 40:4919-27. 10.1007\/s12325-023-02634-7","journal-title":"Adv Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01457-9","article-title":"Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system","volume":"42","author":"Xia C","year":"2024","unstructured":"Xia C, Liu Z, Liu J, Lin L, Chen M. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system. Invest New Drugs. 2024, 42:500-9. 10.1007\/s10637-024-01457-9","journal-title":"Invest New Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00932-8","article-title":"Coadministration of apalutamide and relugolix in patients with localized prostate cancer at high risk for metastases","volume":"18","author":"Brown G","year":"2023","unstructured":"Brown G, Belkoff L, Hafron JM, et al.. Coadministration of apalutamide and relugolix in patients with localized prostate cancer at high risk for metastases. Target Oncol. 2023, 18:95-103. 10.1007\/s11523-022-00932-8","journal-title":"Target Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1135","article-title":"622P Geographical assessment of efficacy and safety of relugolix: a subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)","volume":"32","author":"Bossi A","year":"2021","unstructured":"Bossi A, Shore ND, Tutrone R, et al.. 622P Geographical assessment of efficacy and safety of relugolix: a subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC). Ann Oncol. 2021, 32:S662. 10.1016\/j.annonc.2021.08.1135","journal-title":"Ann Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.5075","article-title":"Impact of age on efficacy and safety of relugolix: a subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer","volume":"39","author":"Cookson M","year":"2021","unstructured":"Cookson M, Shore ND, George DJ, et al.. Impact of age on efficacy and safety of relugolix: a subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer. J Clin Oncol. 2021, 39:5075. 10.1200\/jco.2021.39.15_suppl.5075","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.6_suppl.105","article-title":"Efficacy and safety of relugolix in black men with advanced prostate cancer: a subgroup analysis from the randomized, phase 3 HERO study versus leuprolide","volume":"16","author":"George DJ","year":"2022","unstructured":"George DJ, Saad F, Pieczonka CM, et al.. Efficacy and safety of relugolix in black men with advanced prostate cancer: a subgroup analysis from the randomized, phase 3 HERO study versus leuprolide. J Clin Oncol. 2022, 16:105. 10.1200\/jco.2022.40.6_suppl.105","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.5073","article-title":"Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): a subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU)","volume":"40","author":"Saad F","year":"2022","unstructured":"Saad F, George DJ, Cookson M, et al.. Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): a subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU). J Clin Oncol. 2022, 40:5073. 10.1200\/jco.2022.40.16_suppl.5073","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.198","article-title":"161MO Efficacy and safety of relugolix in Asian men with advanced prostate cancer (APC): a subgroup analysis from the randomized, phase III HERO study versus leuprolide","volume":"33","author":"Ye D","year":"2022","unstructured":"Ye D, Choi YD, Brown, et al.. 161MO Efficacy and safety of relugolix in Asian men with advanced prostate cancer (APC): a subgroup analysis from the randomized, phase III HERO study versus leuprolide. Ann Oncol. 2022, 33:S1497. 10.1016\/j.annonc.2022.10.198","journal-title":"Ann Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.09.007","article-title":"Impact of relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study","volume":"84","author":"Tombal B","year":"2023","unstructured":"Tombal B, Collins S, Morgans AK, et al.. Impact of relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study. Eur Urol. 2023, 84:579-87. 10.1016\/j.eururo.2023.09.007","journal-title":"Eur Urol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000002593.08","article-title":"Pd35-08 Oral relugolix for androgen deprivation therapy in advanced prostate cancer: pooled safety analyses from randomized controlled studies","volume":"207","author":"Bailen JL","year":"2022","unstructured":"Bailen JL, Saad F, George DJ, et al.. Pd35-08 Oral relugolix for androgen deprivation therapy in advanced prostate cancer: pooled safety analyses from randomized controlled studies. J Urol. 2022, 207:e630. 10.1097\/ju.0000000000002593.08","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.301","article-title":"Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): an initial analysis of patient treatment preferences and quality of life","volume":"42","author":"Patel SA","year":"2024","unstructured":"Patel SA, Goyal S, Liu Y, et al.. Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): an initial analysis of patient treatment preferences and quality of life. J Clin Oncol. 2024, 42:301. 10.1200\/jco.2024.42.4_suppl.301","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432059-clinical-effectiveness-of-oral-relugolix-in-advanced-prostate-cancer-a-structured-review-of-current-primary-research","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:31:49Z","timestamp":1763559109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432059-clinical-effectiveness-of-oral-relugolix-in-advanced-prostate-cancer-a-structured-review-of-current-primary-research"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.97231","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}